Citadel Advisors’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-62,700
| Closed | -$257K | – | 14849 |
|
|
2022
Q1 | $257K | Sell |
62,700
-5,300
| -8% | -$19.2K | ﹤0.01% | 10947 |
|
|
2021
Q4 | $243K | Buy |
68,000
+27,900
| +70% | +$97.6K | ﹤0.01% | 11428 |
|
|
2021
Q3 | $146K | Buy |
40,100
+18,700
| +87% | +$75.6K | ﹤0.01% | 12414 |
|
|
2021
Q2 | $93K | Buy |
21,400
+3,100
| +17% | +$12.6K | ﹤0.01% | 12975 |
|
|
2021
Q1 | $75K | Buy |
18,300
+2,300
| +14% | +$9.97K | ﹤0.01% | 12698 |
|
|
2020
Q4 | $64K | Sell |
16,000
-1,900
| -11% | -$6.15K | ﹤0.01% | 10471 |
|
|
2020
Q3 | $48K | Sell |
17,900
-3,700
| -17% | -$10.2K | ﹤0.01% | 9616 |
|
|
2020
Q2 | $59K | Buy |
+21,600
| New | +$60.3K | ﹤0.01% | 9235 |
|
|
2020
Q1 | – | Sell |
-12,700
| Closed | -$60K | – | 10440 |
|
|
2019
Q4 | $60K | Buy |
+12,700
| New | +$52K | ﹤0.01% | 8708 |
|
|
2019
Q3 | – | Sell |
-10,700
| Closed | -$35K | – | 9990 |
|
|
2019
Q2 | $35K | Sell |
10,700
-11,600
| -52% | -$33.6K | ﹤0.01% | 8834 |
|
|
2019
Q1 | $68K | Buy |
+22,300
| New | +$72.3K | ﹤0.01% | 8709 |
|
|
2018
Q4 | – | Sell |
-40,500
| Closed | -$136K | – | 10013 |
|
|
2018
Q3 | $136K | Buy |
+40,500
| New | +$125K | ﹤0.01% | 8446 |
|
|
2016
Q4 | – | Sell |
-15,000
| Closed | -$25K | – | 8062 |
|
|
2016
Q3 | $25K | Buy |
+15,000
| New | +$18.4K | ﹤0.01% | 6997 |
|
|
2015
Q4 | – | Sell |
-2,300
| Closed | -$4K | – | 9385 |
|
|
2015
Q3 | $4K | Sell |
2,300
-1,900
| -45% | -$3.72K | ﹤0.01% | 8672 |
|
|
2015
Q2 | $9K | Sell |
4,200
-300
| -7% | -$727 | ﹤0.01% | 8449 |
|
|
2015
Q1 | $12K | Buy |
4,500
+1,000
| +29% | +$2.54K | ﹤0.01% | 8156 |
|
|
2014
Q4 | $9K | Buy |
3,500
+1,000
| +40% | +$2.25K | ﹤0.01% | 8163 |
|
|
2014
Q3 | $5K | Buy |
2,500
+900
| +56% | +$1.96K | ﹤0.01% | 7928 |
|
|
2014
Q2 | $4K | Sell |
1,600
-9,600
| -86% | -$28.9K | ﹤0.01% | 7773 |
|
|
2014
Q1 | $39K | Sell |
11,200
-8,500
| -43% | -$37.7K | ﹤0.01% | 6932 |
|
|
2013
Q4 | $88K | Buy |
19,700
+17,500
| +795% | +$71.3K | ﹤0.01% | 5711 |
|
|
2013
Q3 | $9K | Buy |
2,200
+1,800
| +450% | +$7.86K | ﹤0.01% | 6494 |
|
|
2013
Q2 | $2K | Buy |
+400
| New | +$1.54K | ﹤0.01% | 6420 |
|
Other funds holding ATRS
Citadel Advisors's ATRS Position: Q2 2022 in Review
Citadel Advisors sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 448,691 shares — an estimated $1.84M sold.
Citadel Advisors first reported a position in ATRS in Q2 2013 and held it in 34 quarters. The position peaked at $1.84M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Citadel Advisors reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 448,691 Antares Pharma, Inc. shares in Q2 2022, an estimated $1.84M.
- Citadel Advisors first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 34 quarters.
- Citadel Advisors's Antares Pharma, Inc. position peaked at $1.84M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.